We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Profiling of Blood Transcriptome Predicts Complications in Pregnancies

By LabMedica International staff writers
Posted on 15 Apr 2019
Print article
Image: Researchers identified an RNA signature in the blood of pregnant lupus patients that could help predict the development of preeclampsia (Photo courtesy of Medical Xpress).
Image: Researchers identified an RNA signature in the blood of pregnant lupus patients that could help predict the development of preeclampsia (Photo courtesy of Medical Xpress).
Researchers have proposed profiling of the blood transcriptome as a method to predict complications in pregnancy that might be experienced by women with systemic lupus erythematosus.

Systemic lupus erythematosus carries an increased risk of pregnancy complications, including preeclampsia and fetal adverse outcomes. To identify the underlying molecular mechanisms responsible for this risk, investigators at Weill Cornell Medicine (New York, NY, USA) longitudinally profiled the blood transcriptome of 92 lupus patients and 43 healthy women during pregnancy and postpartum and performed multicolor flow cytometry in a subset of them.

The transcriptome is the set of all RNA molecules in a cell or a population of cells. It is sometimes used to refer to all RNAs, or just mRNA, depending on the particular experiment. It differs from the exome in that it includes only those RNA molecules found in a specified cell population, and usually includes the amount or concentration of each RNA molecule in addition to the molecular identities. Since it includes all mRNA transcripts in the cell, the transcriptome reflects the genes that are being actively expressed at any given time.

The investigators also profiled 25 healthy women undergoing assisted reproductive technology to monitor transcriptional changes around the time of embryo implantation.

Results indicated that during healthy pregnancy there was a sustained down-regulation of multiple immune signatures, including interferon and plasma cells. These changes appeared early after embryo implantation and were mirrored in uncomplicated lupus pregnancies. Patients with preeclampsia displayed early up-regulation of neutrophil signatures that correlated with expansion of immature neutrophils.

Lupus pregnancies with fetal complications carried the highest interferon and plasma cell signatures as well as activated CD4+ T-cell counts. Therefore, blood immunomonitoring revealed that both healthy and uncomplicated lupus pregnancies exhibited early and sustained transcriptional modulation of lupus-related signatures. Lack of this modulation was associated with adverse outcomes.

"Overall, we have identified significant changes in immune pathways during healthy pregnancy and found that failure to modulate them properly is associated with complications in pregnant lupus patients," said senior author Dr. Virginia Pascual, professor of pediatrics at Weill Cornell Medicine. "Our findings provide a framework for future studies aimed at developing therapeutic strategies to improve health outcomes for mothers with lupus and their offspring."

The work was published in the April 8, 2019, online edition of the Journal of Experimental Medicine.

Related Links:
Weill Cornell Medicine

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.